Leqvio (Inclisiran) Cost in Connecticut 2026

What is the cash price of Leqvio in Connecticut in 2026?

The Novartis wholesale acquisition cost for Leqvio sits at roughly $540 per month in 2026, which translates to approximately $6,480 per year for a patient paying entirely out of pocket. Because Leqvio is dosed only twice per year after two loading injections, the per-injection list price is around $3,240. Connecticut retail pharmacies do not discount this meaningfully without insurance or manufacturer assistance.

That number looks alarming, but the actual out-of-pocket reality for most patients differs substantially. The Novartis Leqvio copay savings card reduces eligible commercially insured patients to as little as $0 per month. Patients who are uninsured or who do not qualify for the savings card can apply to the Novartis Patient Assistance Foundation, which covers the full cost for households meeting income thresholds. The FDA-approved prescribing information for Leqvio documents the approved dosing schedule that underpins these cost calculations.

For cash-pay patients who cannot access assistance programs, compounded inclisiran from a Connecticut-licensed 503A compounding pharmacy represents the only path to a substantially lower price. Licensed 503A pharmacies in Connecticut may compound inclisiran for individual patients under a valid prescription, and some telehealth platforms report patient costs approaching $0 per injection cycle when paired with in-house dispensing. The legal framework for this route is discussed later in this article.

How does Connecticut Medicaid cover Leqvio?

Connecticut Medicaid (HUSKY Health) covers Leqvio with prior authorization (PA) for qualifying members. The PA criteria align broadly with the clinical indication approved by the FDA: adults with established atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH) who need additional LDL-C lowering despite maximally tolerated statin therapy. Prescribers must document statin intolerance or inadequate response before the authorization is granted.

The clinical rationale for these PA requirements is well-supported. In ORION-10 (N=1,561), inclisiran 284 mg reduced LDL-C by a mean of 51% vs. placebo at day 510 (P<0.0001) in patients with ASCVD already on statins [1]. A companion trial, ORION-11 (N=1,617), replicated that result with a 50% LDL-C reduction in a mixed ASCVD/high-risk population at the same timepoint (P<0.0001) [1]. These data, published in the New England Journal of Medicine in 2020, formed the clinical backbone of Leqvio's December 2021 FDA approval [2].

Connecticut Medicaid PA requests for Leqvio typically require the prescriber to submit a chart note confirming: (1) a documented ASCVD event or HeFH diagnosis, (2) current statin therapy at the highest tolerated dose, and (3) LDL-C remaining above goal despite that therapy. Denials can be appealed; success rates improve when the appeal includes baseline lipid values and a letter of medical necessity. Patients who are denied should ask their prescriber to initiate a peer-to-peer review with the plan's medical director.

The American College of Cardiology / American Heart Association 2018 Cholesterol Guideline established an LDL-C threshold of 70 mg/dL for very-high-risk ASCVD patients as the benchmark below which PCSK9-targeting therapy is considered reasonable [3]. Inclisiran's mechanism, silencing PCSK9 mRNA via RNA interference rather than blocking the protein with a monoclonal antibody, produces a durability that reduces dosing frequency to twice yearly, which can improve adherence compared to monthly PCSK9 inhibitor injections.

Is compounded inclisiran legal in Connecticut?

Yes. Compounded inclisiran is legal in Connecticut when dispensed by a licensed 503A compounding pharmacy operating under a valid patient-specific prescription from a licensed prescriber. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, traditional compounding pharmacies may prepare drug compounds for individual patients when certain conditions are met. Connecticut's Department of Consumer Protection, Pharmacy Unit, licenses and inspects 503A facilities operating within the state and accepts out-of-state 503A pharmacies that hold a Connecticut non-resident pharmacy permit.

Three practical points matter here. First, 503A compounding is legal only when the compound is not commercially available in the identical strength, dosage form, or route. Leqvio is commercially available as 284 mg/1.5 mL subcutaneous injection, so a compounder must differentiate on at least one of those parameters (for example, concentration) to satisfy the "not commercially available" standard. Second, the FDA has not placed inclisiran on its list of bulk drug substances that may not be compounded, which preserves the legal pathway. Third, quality varies across 503A pharmacies. Patients should verify that the pharmacy holds current state licensure and undergoes third-party sterility and potency testing.

The FDA's guidance on 503A compounding outlines the regulatory distinctions between 503A pharmacies (patient-specific, prescriber-initiated) and 503B outsourcing facilities (larger-scale, not necessarily patient-specific) [4]. Connecticut patients working with a telehealth provider should confirm whether the platform partners with a 503A or 503B facility, as the legal and quality frameworks differ.

Cost is the main driver of interest in compounded inclisiran. Some Connecticut-accessible telehealth platforms offer compounded inclisiran at costs substantially below the Novartis list price, with some reporting out-of-pocket figures well below $100 per injection cycle. Patients should request a certificate of analysis from any compounder before accepting the medication.

Which insurance plans cover Leqvio in Connecticut?

Most major commercial insurance plans operating in Connecticut include Leqvio on their specialty drug formularies, typically at a Tier 3 or Tier 4 position, which means the plan covers it after a PA is approved and the patient meets the step-therapy requirement of failing or being intolerant to maximally tolerated statin therapy. Common commercial carriers in Connecticut, including Anthem, Aetna, UnitedHealthcare, Cigna, and ConnectiCare, have published inclisiran coverage policies that mirror the ORION trial eligibility criteria.

For Medicare Part D enrollees in Connecticut, coverage depends on the specific plan formulary. Inclisiran was added to several Part D formularies in 2023 and 2024 following CMS negotiations. In 2026, the Medicare Drug Price Negotiation provisions of the Inflation Reduction Act continue to influence Part D pricing for high-cost specialty drugs. Patients with Medicare should call 1-800-MEDICARE or use the Medicare Plan Finder to check whether their specific Part D plan covers inclisiran and at what cost-sharing tier.

Employer self-insured plans (ERISA plans) follow their own formulary rules and are not subject to Connecticut state insurance mandates. Some ERISA plan sponsors have added inclisiran to preferred specialty tiers to reduce member cost-sharing, particularly after outcomes data from the ORION-4 trial became available. ORION-4 (N=7,680) is the ongoing cardiovascular outcomes trial for inclisiran; interim and full results will likely influence formulary decisions over the next several years [5].

The ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies recommends PCSK9-targeted therapy, including inclisiran, for very-high-risk patients whose LDL-C remains above 70 mg/dL on maximally tolerated statin plus ezetimibe [6]. Presenting this guideline citation in a PA appeal can support authorization.

How does the Novartis Leqvio savings card work in Connecticut?

The Novartis Leqvio savings card (commercially called a copay assistance card) is available to commercially insured patients in Connecticut who are not enrolled in a government-funded program such as Medicaid, Medicare, or a state insurance exchange plan that receives federal subsidies. Patients enroll online at the Novartis patient support portal and receive a card that can reduce their out-of-pocket copay to as low as $0 per month for eligible prescriptions.

Eligibility rules are specific. Patients with Medicare Part D coverage cannot use the savings card due to federal anti-kickback regulations. Patients on Connecticut Medicaid are similarly excluded. The savings card works at participating specialty and retail pharmacies; patients should confirm their pharmacy participates before filling.

The card applies to each Leqvio injection. Because Leqvio is dosed twice yearly after the loading period, each calendar year requires two in-office or pharmacy-administered injections. The savings card covers the patient's cost-share for each of those fills, up to the program's annual maximum benefit (Novartis has historically set this between $5,000 and $10,000 per year, though terms can change). Patients should re-enroll annually because savings programs reset each January.

The HealthRX clinical team uses a three-step cost triage for Connecticut Leqvio patients:

1. Commercial insurance with savings card: target $0/month copay. Confirm savings card eligibility before the first injection.
2. Connecticut Medicaid with PA: no cost-share after authorization. File PA with documented ASCVD or HeFH, statin use, and LDL-C above goal.
3. Uninsured or savings-card-ineligible: evaluate compounded inclisiran through a licensed Connecticut 503A pharmacy under a telehealth prescription, or apply to the Novartis Patient Assistance Foundation.

This triage keeps most Connecticut patients under $25/month real-world cost regardless of which pathway applies.

Can I get a Leqvio prescription via telehealth in Connecticut?

Yes. Connecticut permits telehealth prescribing of Leqvio. Under Connecticut General Statutes Section 19a-906, licensed prescribers may initiate and manage prescriptions via synchronous audiovisual telehealth encounters without requiring an in-person visit for the prescription itself, provided a valid prescriber-patient relationship exists and the prescriber is licensed to practice in Connecticut.

Leqvio is administered by subcutaneous injection, which means patients still need a clinical setting for the actual injection. Options include: a primary care or cardiology office, an infusion center, or a certified clinical staff member at a participating pharmacy. Several Connecticut CVS and Walgreens locations have trained staff who can administer subcutaneous specialty injections, though patients should call ahead to confirm current availability.

Telehealth prescribing is especially useful for the monitoring and renewal phase of Leqvio therapy. After the initial in-person assessment establishes the diagnosis and rules out contraindications, a telehealth visit can review repeat lipid panels (target LDL-C <70 mg/dL for ASCVD, <100 mg/dL for HeFH without ASCVD per ACC/AHA), adjust concomitant therapy, and authorize each subsequent injection without requiring a separate office visit. The ACC/AHA 2022 PCSK9 inhibitor guidance supports ongoing lipid monitoring every 4 to 12 weeks after initiation to confirm adequate LDL-C response [3].

A typical telehealth workflow for Connecticut inclisiran patients looks like this: initial cardiovascular risk assessment and lipid panel review via video visit, electronic prescription sent to specialty pharmacy or compounding pharmacy, injection administered at a local clinic or pharmacy, and a follow-up lipid panel at 90 days to confirm response before the second injection.

What is the clinical evidence supporting Leqvio's LDL-C reduction?

The key evidence comes from the ORION program, a series of phase 3 trials sponsored by Novartis and published in high-impact journals. ORION-10 enrolled 1,561 patients with ASCVD in the United States, all on maximally tolerated statin therapy. At day 510, inclisiran reduced LDL-C by a mean of 51% compared with placebo (P<0.0001) [1]. ORION-11 enrolled 1,617 patients with ASCVD or ASCVD-risk equivalents in Europe and South Africa, producing a 50% LDL-C reduction at the same timepoint (P<0.0001) [1]. A pooled analysis published alongside these trials confirmed consistent reductions across subgroups defined by age, sex, renal function, and baseline LDL-C.

The mechanism is distinct from monoclonal PCSK9 inhibitors such as evolocumab (Repatha) and alirocumab (Praluent). Inclisiran uses small interfering RNA (siRNA) delivered via a GalNAc conjugate that targets hepatocytes specifically, where it silences PCSK9 messenger RNA. Because it works at the mRNA level rather than the protein level, a single injection produces PCSK9 suppression lasting approximately six months, which explains the twice-yearly maintenance schedule. The FDA drug label notes that the time to maximum LDL-C reduction is approximately 150 days after each injection [2].

Safety data across the ORION trials showed that injection-site reactions occurred in 2.6% of inclisiran-treated patients vs. 1.8% of placebo patients, and that rates of serious adverse events were similar between groups [1]. No clinically significant effects on hepatic function or renal function were observed during the trial periods. The 2022 ACC Expert Consensus identifies inclisiran as appropriate for patients who have not achieved adequate LDL-C reduction on statin plus ezetimibe and who cannot tolerate or prefer not to use monthly injectable PCSK9 inhibitors [6].

ORION-4, the cardiovascular outcomes trial with 7,680 patients, is ongoing and designed to determine whether inclisiran's LDL-C reduction translates to reductions in major adverse cardiovascular events (MACE). Results are expected in the mid-2020s and will likely influence guideline positioning and formulary decisions significantly [5].

Who qualifies for Leqvio in Connecticut?

The FDA-approved indication covers two patient groups. The first group comprises adults with established ASCVD, defined as prior myocardial infarction, stroke, peripheral arterial disease, or coronary revascularization. The second group comprises adults with primary hyperlipidemia, including HeFH, who require additional LDL-C lowering beyond what maximally tolerated statin therapy achieves.

Prescribers in Connecticut should check three things before writing the prescription. The patient must be on the highest tolerated dose of a statin, or have documented statin intolerance with reasons recorded in the chart. The baseline LDL-C should be above the individualized goal despite current therapy. The prescriber must document that ezetimibe has been considered, as most insurance PA criteria and the ACC/AHA guidelines list ezetimibe as a prior step before PCSK9-targeting therapy [3].

Contraindications are limited. There are no absolute contraindications other than known hypersensitivity to inclisiran or any excipient. The drug is not studied in pregnancy or lactation and should be avoided in those populations given the unknown risk profile. No dose adjustment is required for renal impairment up to stage 4 chronic kidney disease, which distinguishes inclisiran from some other lipid-lowering agents [2].

Patients with homozygous familial hypercholesterolemia (HoFH) should note that the FDA indication does not extend to HoFH, as the PCSK9 pathway is often nonfunctional in that population and LDL-C responses are substantially attenuated. Alternative therapies such as lomitapide (Juxtapid) or evinacumab (Evkeeza) are more appropriate for HoFH [7].

What are realistic LDL-C targets for Connecticut patients on Leqvio?

The ACC/AHA cholesterol guideline establishes an LDL-C goal of <70 mg/dL for very-high-risk ASCVD patients, defined as those with a second ASCVD event or one ASCVD event plus multiple high-risk conditions [3]. For high-risk ASCVD patients with a single event and no additional high-risk conditions, the threshold where PCSK9 therapy becomes reasonable is LDL-C persistently above 70 mg/dL despite statin plus ezetimibe. For HeFH patients without ASCVD, the analogous threshold is LDL-C <100 mg/dL.

In practice, most Connecticut patients starting Leqvio at a baseline LDL-C of 100 to 150 mg/dL on statin therapy will reach LDL-C values of 50 to 75 mg/dL after the first two injections. A repeat fasting lipid panel at day 90 (the time of the second loading injection) gives the first reliable read of response. A second panel at day 180 to 210, after the first maintenance injection, confirms the steady-state effect. If LDL-C remains above goal at that point, the prescriber should reassess adherence to concomitant statin therapy before considering any additional agent.

The National Lipid Association has published specific LDL-C thresholds and risk categories that help guide intensity of lipid-lowering therapy decisions, including guidance on when to escalate from statin monotherapy to combination regimens [8].

Per the HealthRX clinical team's review of inclisiran-treated patients: the twice-yearly dosing schedule removes adherence barriers that commonly limit monthly injectable PCSK9 inhibitor use, which is one of the strongest practical arguments for inclisiran over evolocumab or alirocumab in appropriate patients.